MaxCyte to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MaxCyte, focused on cell-engineering, announced participation in two upcoming investor conferences. The Stifel Healthcare Conference is scheduled for November 16, 2022, at 3:00 PM ET, followed by the Stephens Annual Investment Conference on November 17, 2022, at 10:00 AM ET. Webcasts of these events will be accessible on the company’s investor relations website. MaxCyte develops technologies for cell-based therapeutics, including its proprietary Flow Electroporation® technology and ExPERT™ platform, aimed at supporting the cell therapy market.

ROCKVILLE, Md., Nov. 02, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, today announced Company management will participate in the following investor conferences:

• Stifel Healthcare Conference
  Wednesday, November 16^th at 3:00 p.m. Eastern Time
  

• Stephens Annual Investment Conference
  Thursday, November 17^th at 10:00 a.m. Eastern Time
  

Live and archived webcasts of the events will be available on the “Events” section of the MaxCyte investor relations website at https://investors.maxcyte.com/.

About MaxCyte

MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support innovative, cell-based research. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® technology, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
jr@maxcyte.com

US Media Relations
Seismic Collaborative, A Spectrum Science Company
Valerie Enes
+1 408-497-8568
valerie@teamseismic.com

Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500

UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com

FAQ

What conferences will MaxCyte participate in November 2022?

MaxCyte will participate in the Stifel Healthcare Conference on November 16, 2022, and the Stephens Annual Investment Conference on November 17, 2022.

What is the significance of MaxCyte's Flow Electroporation technology?

MaxCyte's Flow Electroporation technology is crucial for the engineering of diverse cell types, supporting advancements in cell-based therapeutics.

When will the Stifel Healthcare Conference be held?

The Stifel Healthcare Conference will be held on November 16, 2022, at 3:00 PM Eastern Time.

Where can I watch the webcasts of MaxCyte's conference presentations?

Webcasts of MaxCyte's conference presentations will be available on their investor relations website under the 'Events' section.

What is MaxCyte's stock symbol?

MaxCyte is listed under the stock symbol MXCT.